|
bnt162b2 vaccine |
6 |
|
clustering |
6 |
|
genetic risk predisposition |
6 |
|
vaccine side effect |
6 |
|
vaccine-induced myocarditis |
6 |
|
adolescent |
4 |
|
covid-19 vaccines |
4 |
|
echocardiography |
4 |
|
magnetic resonance imaging |
4 |
|
myocarditis |
4 |
|
treatment outcome |
4 |
|
catheter ablation |
3 |
|
congenital heart disease |
3 |
|
long qt syndrome |
3 |
|
pediatric |
3 |
|
ablation |
2 |
|
atrial tachycardia |
2 |
|
cryoablation |
2 |
|
heart block |
2 |
|
high density |
2 |
|
intraatrial reentrant tachycardia |
2 |
|
pediatrics |
2 |
|
variant classification |
2 |
|
vus |
2 |
|
adult congenital heart disease |
1 |
|
ambulatory care information systems |
1 |
|
ar acute rejection |
1 |
|
arrhythmia |
1 |
|
atrioventricular node |
1 |
|
avnrt |
1 |
|
cad coronary artery disease |
1 |
|
cardiomyopathy |
1 |
|
catecholamines |
1 |
|
chd |
1 |
|
clinical care |
1 |
|
electrocardiogram (ecg) |
1 |
|
electrocardiography |
1 |
|
electronic health records |
1 |
|
electrophysiology |
1 |
|
emb endomyocardial biopsies |
1 |
|
fetal bradycardia |
1 |
|
fetal echocardiography |
1 |
|
fetal magnetocardiography |
1 |
|
fontan |
1 |
|
fontan operation |
1 |
|
heart failure |
1 |
|
hla human leukocyte antigen |
1 |
|
hypertrophy, left ventricular |
1 |
|
implantable cardioverter-defibrillator |
1 |
|
in vivo model |
1 |
|
maze procedure |
1 |
|
multicenter |
1 |
|
obesity |
1 |
|
outcomes |
1 |
|
pacemakers |
1 |
|
pacing |
1 |
|
palpitations |
1 |
|
pra panel-reactive antibody |
1 |
|
preexcitation |
1 |
|
quality |
1 |
|
quality improvement |
1 |
|
reference value |
1 |
|
regenerative medicine |
1 |
|
registry |
1 |
|
risk stratification |
1 |
|
single ventricle |
1 |
|
sudden death |
1 |
|
supraventricular tachycardia (svt) |
1 |
|
svt |
1 |
|
tissue engineering |
1 |
|
univentricular heart |
1 |
|
ventricular fibrillation |
1 |
|
ventricular pre-excitation |
1 |
|
ventricular tachycardia |
1 |
|
wolff-parkinson-white (wpw) syndrome |
1 |
|
wolff-parkinson-white syndrome |
1 |
